Day: September 23, 2020

Manuscript describes preclinical development of MGC018Phase 1 dose expansion trial evaluating MGC018 in patients with mCRPC, TNBC and NSCLC is currently recruiting patientsROCKVILLE, MD, Sept. 23, 2020 (GLOBE NEWSWIRE) — MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, highlighting the development of MGC018, the Company’s investigational antibody-drug conjugate (ADC) targeting B7-H3 for the treatment of solid tumors.B7-H3 has been identified as a cell surface protein with limited expression on normal tissues but over-expressed on the epithelium and...

Company Announcement No. 23 Aalborg, 23. September 2020 Seluxit presents an annual report, demonstrating the ability to deliver on revenue and result – while creating an interesting pipeline of products for future growth.Daniel Lux, CEO:“Some of the results which our dedicated staff and great partners have created and which I would like to highlight are:175.000 delivered radio modules for Smart Meters to the German marketSLX Heartbeat, a new product to monitor heart starters was developed and first installations were made in collaboration with our partners Rapid Prototyping Kit – launch of our standard development tools and a webshop where these can be bought directlyA growth in revenue by 17% despite a challenging second half of the fiscal yearThe goal for 2019/20 was to create business visibility in the market, grow our...

Selskabsmeddelelse nr. 23 Aalborg, 23. september 2020 Seluxit præsenterer en årsrapport, der demonstrerer evnen til at levere omsætning og resultat – samtidig med, at der skabes en interessant pipeline af produkter til fremtidig vækst.Daniel Lux, CEO udtaler:”Nogle af de resultater, som vores dedikerede medarbejdere og gode partnere har skabt, og som jeg gerne vil fremhæve, er:175.000 leverede radiomoduler til Smart Meters til det tyske markedSLX Heartbeat, et nyt produkt til overvågning af hjertestartere blev udviklet, og de første installationer er foretaget i samarbejde med vores partnereRapid Prototyping Kit – lancering af vores standardudviklingsværktøjer og en webshop, hvor disse kan købes direkteEn vækst i omsætningen med 17%, på trods af en udfordrende anden halvdel af regnskabsåretMålet for 2019/20 var at skabe forretningssynlighed...

ALPHARETTA, Ga., Sept. 23, 2020 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today several clinical data presentations were given at the virtual 53rd Annual Scientific Meeting of The Retina Society.Clearside also announced that data from the Company’s Phase 2 clinical trial in diabetic macular edema (DME) was published in Ophthalmology Retina and can be accessed here. The trial, entitled TYBEE, evaluated the investigational drug XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) when used with intravitreally administered aflibercept in patients with DME over a 6-month evaluation period. This early data suggests that, if approved,...

BALA CYNWYD, Pa., Sept. 23, 2020 (GLOBE NEWSWIRE) — Leading private markets asset management firm Hamilton Lane (NASDAQ: HLNE) today announced the appointment of longtime Managing Director Paul Yett to the role of Director of ESG & Sustainability. Hamilton Lane has demonstrated a long-standing commitment to ESG, sustainability and responsible investing, and Yett will focus on expanding and formally spearheading the firm’s ESG integration strategy going forward.His responsibilities will include managing ESG integration throughout the investment processes across the Fund, Direct Investment, Secondary, Real Asset and Direct Credit teams; driving ESG policy development and advising deal teams during due diligence; supporting clients, government entities and other stakeholders in regards to ESG and sustainability matters; and overseeing...

 Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”)Preliminary Results for the year ended 30 June 2020Record level of pre R&D operating profit supported by robust sales and operational efficiencyStrong cash position with Grass MATA MPL Phase III programme and initial Phase I peanut trial fully fundedExclusive licencing agreement signed for further virus like particle(VLP) candidates             23 September 2020 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapy, today announces its preliminary results for the year ended 30 June 2020.Financial Highlights7% revenue growth at constant rate* and 6% at reported rate to £78.2m (2019: £73.7m)25% increase in pre-R&D operating profit to £14.2m (2019: £11.3m) as a result of sales growth...

AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT SUPPORTS GLOBAL FH AWARENESS DAY – SEPTEMBER 24, 2020DUBLIN, Ireland, and Boston MA, September 23 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces its support today for Global FH Awareness Day 2020 which will take place on Thursday, September 24, 2020.Dr Joe Wiley, CEO of Amryt Pharma, commented: “All of the Amryt team are pleased to support the great work of the FH Foundation in the US and FH Europe as they seek to raise awareness of FH and HoFH amongst patients, clinicians and the wider community. For our part, we are collaborating with all stakeholders to continue to deliver therapies to patients...

STOCKHOLM, Sweden and WATERTOWN, Mass., Sept. 23, 2020 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Selecta Biosciences, Inc. (Nasdaq: SELB) today announced the commencement of the phase 3 clinical program of SEL-212 for chronic refractory gout, with the randomization of the first patient in the study.“We are pleased to have commenced the phase 3 DISSOLVE program evaluating SEL-212 in two phase 3 double-blind, placebo-controlled studies,” said Carsten Brunn, Ph.D., President and CEO of Selecta. “SEL-212 serves as an important validation of Selecta’s ImmTORTM platform, and we are proud to have advanced it into late-stage clinical studies. In partnership with Sobi, we look forward to enrolling patients in the studies and continuing to evaluate SEL-212 as a new, once-monthly treatment option for patients...

– Band n79 Filter for New Small Cell Product Aimed at 5G Network Operators –– Akoustis Expects Production Ramp in Early CY21 –Charlotte, N.C., Sept. 23, 2020 (GLOBE NEWSWIRE) — Akoustis Technologies, Inc. (NASDAQ: AKTS) (“Akoustis” or the “Company”), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has received a design win and pre-production order for band n79 XBAW™ filters from a new 5G small cell network infrastructure customer. This is the second customer in 5G small cell infrastructure where Akoustis now has more than five active engagements.The new customer has completed sampling of the Akoustis band n79 filter and plans to use the current order to complete qualification and test its new 5G network infrastructure...

BUFFALO, N.Y., Sept. 23, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy targeting solid tumors that are NY-ESO-1 positive in HLA-A*02:01 positive patients.TCRT-ESO-A2 is being developed by Axis Therapeutics Limited, a joint venture between Athenex and Xiangxue Life Sciences Limited (“XLifeSc”), a subsidiary of Xiangxue Pharmaceutical Co., Ltd. (Shenzhen Exchange: 300147). TCRT-ESO-A2 is similar to TAEST16001, an autologous cell-based therapy being developed simultaneously...